⚙

Pathophysiology

4

Angiogenic imbalance and sFlt1-mediated vascular dysfunction

The late-pregnant and early postpartum state is characterized by elevated levels of soluble fms-like tyrosine kinase 1 (sFlt1), an anti-angiogenic factor released by the placenta. sFlt1 antagonizes VEGF and PlGF signaling, leading to endothelial dysfunction and impaired cardiac angiogenesis. In susceptible women, this anti-angiogenic state triggers cardiomyocyte damage and systolic dysfunction.

endothelial cell link cardiac muscle cell link

negative regulation of angiogenesis link ↑ INCREASED vascular endothelial growth factor receptor signaling pathway link ↓ DECREASED

Downstream

Oxidative stress and 16-kDa prolactin generation Anti-angiogenic stress in the cardiac vasculature promotes oxidative stress, which triggers cathepsin D cleavage of prolactin into the anti-angiogenic 16-kDa fragment.

Show evidence (2 references)

PMID:22596155 SUPPORT Human Clinical

"plasma samples from women with PPCM contained abnormally high levels of sFLT1. These data indicate that PPCM is mainly a vascular disease, caused by excess anti-angiogenic signalling in the peripartum period"

The Nature 2012 study measured sFLT1 in human PPCM plasma samples, demonstrating elevated anti-angiogenic signaling as the core vascular mechanism underlying PPCM.

PMID:28552862 SUPPORT Human Clinical

"Concentrations of the anti-angiogenic factor soluble fms-like tyrosine kinase-1 (sFlt-1) are altered in peripartum cardiomyopathy (PPCM)"

Clinical biomarker study confirming altered sFlt-1 concentrations in PPCM patients, supporting the anti-angiogenic pathogenesis model.

Oxidative stress and 16-kDa prolactin generation

Oxidative stress in the peripartum myocardium activates cathepsin D, which cleaves full-length prolactin into a 16-kDa N-terminal fragment. This 16-kDa prolactin fragment is strongly anti-angiogenic and pro-apoptotic, damaging the cardiac microvasculature and promoting cardiomyocyte death. This mechanism provided the rationale for bromocriptine therapy in PPCM.

cardiac muscle cell link

response to oxidative stress link ↑ INCREASED proteolysis link

Downstream

Myocardial inflammation and immune activation Oxidative damage and prolactin fragment-mediated vascular injury activate inflammatory cascades in the myocardium.

Cardiomyocyte injury and ventricular dysfunction Direct toxicity of the 16-kDa prolactin fragment and oxidative damage lead to cardiomyocyte apoptosis.

Show evidence (3 references)

PMID:17289576 SUPPORT Model Organism

"female mice with a cardiomyocyte-specific deletion of stat3 develop PPCM. In these mice, cardiac cathepsin D (CD) expression and activity is enhanced and associated with the generation of a cleaved antiangiogenic and proapoptotic 16 kDa form of the nursing hormone prolactin"

Seminal Cell 2007 paper establishing the STAT3/cathepsin D/16-kDa prolactin axis as a key pathogenic mechanism in PPCM, demonstrated in a mouse model.

PMID:17289576 SUPPORT Human Clinical

"Myocardial STAT3 protein levels are reduced and serum levels of activated CD and 16 kDa prolactin are elevated in PPCM patients"

Same study confirmed that the STAT3/cathepsin D/prolactin mechanism identified in mice is also operative in human PPCM patients.

PMID:24448315 SUPPORT Model Organism

"Postpartum Akt activation is detrimental for the peripartum heart as it lowers anti-oxidative defence and in combination with low STAT3 conditions, accelerate cardiac inflammation and fibrosis"

Demonstrates that impaired antioxidative defense (via Akt/STAT3 imbalance) drives cardiac inflammation and fibrosis in the peripartum heart, supporting oxidative stress as a central mechanism.

Myocardial inflammation and immune activation

PPCM is associated with myocardial inflammation, with infiltration of inflammatory cells and elevated proinflammatory cytokines. Autoimmune mechanisms have been implicated, including the development of cardiac autoantibodies. The inflammatory milieu contributes to progressive myocardial damage and ventricular remodeling.

T cell link macrophage link

inflammatory response link ↑ INCREASED adaptive immune response link ⚠ ABNORMAL

Downstream

Cardiomyocyte injury and ventricular dysfunction Sustained inflammation and autoimmune attack contribute to ongoing cardiomyocyte damage and progressive left ventricular dysfunction.

Show evidence (2 references)

PMID:34963460 SUPPORT Human Clinical

"Multivariate analysis identified negativity for anti-M2-R as the independent predictor for the improvement of cardiac function"

Demonstrates that autoantibodies against the M2-muscarinic receptor are present in PPCM patients and independently predict poorer cardiac recovery, supporting an autoimmune component to PPCM pathogenesis.

PMID:37414337 SUPPORT Human Clinical

"Its etiopathogenesis is incompletely understood and is likely multifactorial, including hemodynamic stresses of pregnancy, vasculo-hormonal factors, inflammation, immunology and genetics"

Review confirms inflammation and immunology as recognized pathophysiological contributors to PPCM.

Cardiomyocyte injury and ventricular dysfunction

The convergence of anti-angiogenic stress, oxidative damage, 16-kDa prolactin toxicity, and immune-mediated injury results in cardiomyocyte apoptosis and necrosis. This leads to left ventricular dilation and systolic dysfunction, manifesting as heart failure with reduced ejection fraction.

cardiac muscle cell link

apoptotic process link ↑ INCREASED

Show evidence (1 reference)

PMID:20675664 SUPPORT Human Clinical

"Peripartum cardiomyopathy is a distinct form of cardiomyopathy, associated with a high morbidity and mortality, but also with the possibility of full recovery"

ESC position statement confirms PPCM as a distinct cardiomyopathy with characteristic ventricular dysfunction that can be reversible.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

7

Blood 1

Thromboembolism Thromboembolism (HP:0001907)

Cardiovascular 3

Dilated cardiomyopathy Dilated cardiomyopathy (HP:0001644)

Show evidence (2 references)

PMID:37414337 SUPPORT Human Clinical

"Peripartum cardiomyopathy is a rare type of heart failure manifesting towards the end of pregnancy or in the months following delivery, in the absence of any other cause of heart failure"

Confirms heart failure as the defining clinical manifestation of PPCM.

PMID:20675664 SUPPORT Human Clinical

"It typically develops during the last month of, and up to 6 months after, pregnancy in women without known cardiovascular disease"

ESC position statement defines the temporal presentation of PPCM heart failure.

Left ventricular systolic dysfunction Reduced left ventricular ejection fraction (HP:0012664)

Arrhythmia Arrhythmia (HP:0011675)

Show evidence (2 references)

PMID:30843220 SUPPORT Human Clinical

"One woman was in atrial fibrillation, and all other subjects were in sinus rhythm; 45 (51%) had a normal sinus rhythm, 37 (42%) showed sinus tachycardia, and 5 (6%) showed sinus bradycardia. Ventricular ectopic beats were observed in 3 subjects."

The IPAC cohort documents rhythm abnormalities including atrial fibrillation, sinus tachycardia, sinus bradycardia, and ventricular ectopy among women with PPCM.

PMID:33791817 SUPPORT Human Clinical

"Studies on the use of the wearable cardioverter-defibrillator in patients with PPCM show a substantial burden of ventricular tachyarrhythmias and sudden death in patients with severely reduced left ventricular function."

This review supports ventricular tachyarrhythmias as a clinically relevant rhythm complication in severe PPCM.

Metabolism 1

Peripheral edema Peripheral edema (HP:0012398)

Respiratory 1

Dyspnea Dyspnea (HP:0002094)

Constitutional 1

Fatigue Fatigue (HP:0012378)

🧬

Genetic Associations

1

TTN truncating variants (Truncating variants in titin (TTN) are the most commonly identified genetic risk factor for PPCM, found in approximately 10-15% of cases.)

Show evidence (2 references)

PMID:26735901 SUPPORT Human Clinical

"65% of variants occurred in TTN (in 10% of the patients, P = 2.7×10−10 for the comparison with the reference population). The great majority of these variants occurred in constitutively expressed exons and in the region encoding the A-band"

NEJM 2016 study identified TTN truncating variants in 10% of PPCM patients, predominantly in the A-band, establishing TTN as the most prevalent genetic predisposition.

PMID:26735901 SUPPORT Human Clinical

"the presence of TTN truncating variants was significantly correlated with a lower ejection fraction at 1-year follow-up (P=0.005)"

TTN truncating variants not only predispose to PPCM but also predict worse cardiac recovery, with lower ejection fraction at one year.

💊

Treatments

5

Standard heart failure therapy

Action: Pharmacotherapy NCIT:C15986

Guideline-directed medical therapy for heart failure with reduced ejection fraction, including ACE inhibitors (postpartum), beta-blockers, diuretics, and aldosterone antagonists.

Show evidence (1 reference)

PMID:37414337 SUPPORT Human Clinical

"It includes standard pharmacological therapies for heart failure, within the safety restrictions for pregnancy and lactation"

Review confirms that standard heart failure pharmacotherapy is the foundation of PPCM management, with modifications for pregnancy and lactation safety.

Bromocriptine

Action: Pharmacotherapy NCIT:C15986

Agent: bromocriptine ↗

Bromocriptine, a dopamine agonist that suppresses prolactin secretion, has been investigated as a targeted therapy for PPCM based on the 16-kDa prolactin pathogenesis hypothesis. Evidence from randomized trials suggests benefit in left ventricular recovery.

Mechanism Target:

INHIBITS Oxidative stress and 16-kDa prolactin generation — Bromocriptine suppresses prolactin secretion, preventing cathepsin D cleavage of prolactin into the cardiotoxic 16-kDa fragment.

Show evidence (2 references)

PMID:20308616 SUPPORT Human Clinical

"the addition of bromocriptine to standard heart failure therapy appeared to improve left ventricular ejection fraction and a composite clinical outcome in women with acute severe PPCM"

Proof-of-concept RCT showing bromocriptine added to standard therapy resulted in significantly greater LVEF recovery at 6 months.

PMID:17289576 SUPPORT Model Organism

"Treatment with bromocriptine, an inhibitor of prolactin secretion, prevents the development of PPCM"

Seminal mouse model study demonstrating bromocriptine prevents PPCM by blocking prolactin secretion and its pathogenic 16-kDa cleavage product.

Mechanical circulatory support

Action: mechanical circulatory support Ontology label: surgical procedure MAXO:0000004

In severe cases with cardiogenic shock or refractory heart failure, mechanical circulatory support (ventricular assist devices, ECMO) may be needed as bridge to recovery or transplantation.

Cardiac transplantation

Action: organ transplantation MAXO:0010039

Heart transplantation is considered for patients with severe, refractory PPCM who do not recover ventricular function despite optimal medical therapy and mechanical support.

Anticoagulation

Action: anticoagulant agent therapy MAXO:0000178

Anticoagulation is recommended for PPCM patients with severe left ventricular dysfunction (LVEF <35% in Europe, <30% in the US) due to increased thromboembolic risk. LMWH is preferred during pregnancy; warfarin may be used postpartum. Prophylactic anticoagulation is also advised when bromocriptine is used due to its prothrombotic effects.

🌍

Environmental Factors

3

Pregnancy and peripartum hemodynamic stress

Pregnancy imposes substantial hemodynamic stress including increased blood volume, increased cardiac output, and decreased systemic vascular resistance. The peripartum period represents the maximal hemodynamic load, which in susceptible individuals unmasks or triggers cardiomyopathy.

Show evidence (1 reference)

PMID:22596155 SUPPORT Human Clinical

"This anti-angiogenic environment is accompanied by subclinical cardiac dysfunction, the extent of which correlates with circulating levels of sFLT1"

Human clinical data showing that the anti-angiogenic environment of late pregnancy causes subclinical cardiac dysfunction, supporting the peripartum period as a hemodynamic/hormonal stressor.

Preeclampsia and hypertensive disorders

Preeclampsia and gestational hypertension are significant risk factors for PPCM. The shared anti-angiogenic milieu (elevated sFlt1) mechanistically links these conditions.

Show evidence (2 references)

PMID:24013055 SUPPORT Human Clinical

"The prevalence of PE, hypertensive disorders, and multiple gestations in women with PPCM is markedly higher than that in the general population"

Meta-analysis of 22 studies demonstrates a markedly elevated prevalence of pre-eclampsia in PPCM cohorts compared to the general population.

PMID:24013055 SUPPORT Human Clinical

"These findings support the concept of a shared pathogenesis between PE and PPCM and highlight the need for awareness of the overlap between these 2 diseases"

Supports a mechanistic link between preeclampsia and PPCM through shared anti-angiogenic pathogenesis.

Multiparity and multiple gestations

Multiple pregnancies and twin/higher-order gestations increase PPCM risk, likely through increased hemodynamic stress and elevated anti-angiogenic factor levels.

Show evidence (1 reference)

PMID:22596155 SUPPORT Human Clinical

"In humans, the placenta in late gestation secretes VEGF inhibitors like soluble FLT1 (sFLT1), and this is accentuated by multiple gestation and pre-eclampsia"

Human clinical observation demonstrating that multiple gestation increases anti-angiogenic burden through elevated sFLT1, mechanistically linking multiple gestations to PPCM risk.

🔬

Clinical Trials

1

NCT05180773 PHASE_IV RECRUITING

REBIRTH (Randomized Evaluation of Bromocriptine In Myocardial Recovery THerapy) is a phase 4, randomized, placebo-controlled trial evaluating bromocriptine therapy in 200 women newly diagnosed with PPCM within 5 months postpartum. Primary endpoint is LVEF at 6 months.

Show evidence (1 reference)

clinicaltrials:NCT05180773 SUPPORT

"The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes"

Definitive phase 4 RCT designed to resolve the clinical question of whether bromocriptine improves myocardial recovery in PPCM.

{ }

Source YAML

click to show

name: Peripartum Cardiomyopathy
creation_date: '2026-05-04T12:00:00Z'
updated_date: '2026-05-04T21:06:33Z'
category: Complex
synonyms:
- postpartum cardiomyopathy
- Meadows' syndrome
description: >-
  Peripartum cardiomyopathy (PPCM) is an idiopathic form of dilated cardiomyopathy
  that presents with heart failure secondary to left ventricular systolic dysfunction
  toward the end of pregnancy or in the months following delivery. It is defined by
  an ejection fraction below 45% in the absence of another identifiable cause of
  heart failure. The pathophysiology involves angiogenic imbalance, oxidative stress,
  inflammation, and autoimmune mechanisms. PPCM disproportionately affects women of
  African descent and carries significant morbidity and mortality, though a substantial
  proportion of patients recover ventricular function.
disease_term:
  preferred_term: peripartum cardiomyopathy
  term:
    id: MONDO:0018920
    label: peripartum cardiomyopathy
parents:
- dilated cardiomyopathy
- pregnancy disorder
pathophysiology:
- name: Angiogenic imbalance and sFlt1-mediated vascular dysfunction
  description: >-
    The late-pregnant and early postpartum state is characterized by elevated
    levels of soluble fms-like tyrosine kinase 1 (sFlt1), an anti-angiogenic
    factor released by the placenta. sFlt1 antagonizes VEGF and PlGF signaling,
    leading to endothelial dysfunction and impaired cardiac angiogenesis.
    In susceptible women, this anti-angiogenic state triggers cardiomyocyte
    damage and systolic dysfunction.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: negative regulation of angiogenesis
    term:
      id: GO:0016525
      label: negative regulation of angiogenesis
    modifier: INCREASED
  - preferred_term: vascular endothelial growth factor receptor signaling pathway
    term:
      id: GO:0048010
      label: vascular endothelial growth factor receptor signaling pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:22596155
    reference_title: "Cardiac angiogenic imbalance leads to peripartum cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      plasma samples from women with PPCM contained abnormally high levels
      of sFLT1. These data indicate that PPCM is mainly a vascular disease,
      caused by excess anti-angiogenic signalling in the peripartum period
    explanation: >-
      The Nature 2012 study measured sFLT1 in human PPCM plasma samples,
      demonstrating elevated anti-angiogenic signaling as the core vascular
      mechanism underlying PPCM.
  - reference: PMID:28552862
    reference_title: "Imbalanced Angiogenesis in Peripartum Cardiomyopathy - Diagnostic Value of Placenta Growth Factor."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Concentrations of the anti-angiogenic factor soluble fms-like tyrosine
      kinase-1 (sFlt-1) are altered in peripartum cardiomyopathy (PPCM)
    explanation: >-
      Clinical biomarker study confirming altered sFlt-1 concentrations in PPCM
      patients, supporting the anti-angiogenic pathogenesis model.
  downstream:
  - target: Oxidative stress and 16-kDa prolactin generation
    description: >-
      Anti-angiogenic stress in the cardiac vasculature promotes oxidative
      stress, which triggers cathepsin D cleavage of prolactin into the
      anti-angiogenic 16-kDa fragment.
- name: Oxidative stress and 16-kDa prolactin generation
  description: >-
    Oxidative stress in the peripartum myocardium activates cathepsin D,
    which cleaves full-length prolactin into a 16-kDa N-terminal fragment.
    This 16-kDa prolactin fragment is strongly anti-angiogenic and
    pro-apoptotic, damaging the cardiac microvasculature and promoting
    cardiomyocyte death. This mechanism provided the rationale for
    bromocriptine therapy in PPCM.
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
    modifier: INCREASED
  - preferred_term: proteolysis
    term:
      id: GO:0006508
      label: proteolysis
  evidence:
  - reference: PMID:17289576
    reference_title: "A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      female mice with a cardiomyocyte-specific deletion of stat3 develop
      PPCM. In these mice, cardiac cathepsin D (CD) expression and activity
      is enhanced and associated with the generation of a cleaved
      antiangiogenic and proapoptotic 16 kDa form of the nursing hormone
      prolactin
    explanation: >-
      Seminal Cell 2007 paper establishing the STAT3/cathepsin D/16-kDa
      prolactin axis as a key pathogenic mechanism in PPCM, demonstrated
      in a mouse model.
  - reference: PMID:17289576
    reference_title: "A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Myocardial STAT3 protein levels are reduced and serum levels of
      activated CD and 16 kDa prolactin are elevated in PPCM patients
    explanation: >-
      Same study confirmed that the STAT3/cathepsin D/prolactin mechanism
      identified in mice is also operative in human PPCM patients.
  - reference: PMID:24448315
    reference_title: "Opposing roles of Akt and STAT3 in the protection of the maternal heart from peripartum stress."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Postpartum Akt activation is detrimental for the peripartum heart as
      it lowers anti-oxidative defence and in combination with low STAT3
      conditions, accelerate cardiac inflammation and fibrosis
    explanation: >-
      Demonstrates that impaired antioxidative defense (via Akt/STAT3
      imbalance) drives cardiac inflammation and fibrosis in the peripartum
      heart, supporting oxidative stress as a central mechanism.
  downstream:
  - target: Myocardial inflammation and immune activation
    description: >-
      Oxidative damage and prolactin fragment-mediated vascular injury
      activate inflammatory cascades in the myocardium.
  - target: Cardiomyocyte injury and ventricular dysfunction
    description: >-
      Direct toxicity of the 16-kDa prolactin fragment and oxidative
      damage lead to cardiomyocyte apoptosis.
- name: Myocardial inflammation and immune activation
  description: >-
    PPCM is associated with myocardial inflammation, with infiltration of
    inflammatory cells and elevated proinflammatory cytokines. Autoimmune
    mechanisms have been implicated, including the development of cardiac
    autoantibodies. The inflammatory milieu contributes to progressive
    myocardial damage and ventricular remodeling.
  cell_types:
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
    modifier: INCREASED
  - preferred_term: adaptive immune response
    term:
      id: GO:0002250
      label: adaptive immune response
    modifier: ABNORMAL
  evidence:
  - reference: PMID:34963460
    reference_title: "Impact of autoantibodies against the M2-muscarinic acetylcholine receptor on clinical outcomes in peripartum cardiomyopathy patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Multivariate analysis identified negativity for anti-M2-R as the
      independent predictor for the improvement of cardiac function
    explanation: >-
      Demonstrates that autoantibodies against the M2-muscarinic receptor
      are present in PPCM patients and independently predict poorer cardiac
      recovery, supporting an autoimmune component to PPCM pathogenesis.
  - reference: PMID:37414337
    reference_title: "Peripartum cardiomyopathy: A review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Its etiopathogenesis is incompletely understood and is likely
      multifactorial, including hemodynamic stresses of pregnancy,
      vasculo-hormonal factors, inflammation, immunology and genetics
    explanation: >-
      Review confirms inflammation and immunology as recognized
      pathophysiological contributors to PPCM.
  downstream:
  - target: Cardiomyocyte injury and ventricular dysfunction
    description: >-
      Sustained inflammation and autoimmune attack contribute to ongoing
      cardiomyocyte damage and progressive left ventricular dysfunction.
- name: Cardiomyocyte injury and ventricular dysfunction
  description: >-
    The convergence of anti-angiogenic stress, oxidative damage, 16-kDa
    prolactin toxicity, and immune-mediated injury results in cardiomyocyte
    apoptosis and necrosis. This leads to left ventricular dilation and
    systolic dysfunction, manifesting as heart failure with reduced ejection
    fraction.
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: apoptotic process
    term:
      id: GO:0006915
      label: apoptotic process
    modifier: INCREASED
  evidence:
  - reference: PMID:20675664
    reference_title: "Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Peripartum cardiomyopathy is a distinct form of cardiomyopathy,
      associated with a high morbidity and mortality, but also with the
      possibility of full recovery
    explanation: >-
      ESC position statement confirms PPCM as a distinct cardiomyopathy
      with characteristic ventricular dysfunction that can be reversible.
phenotypes:
- category: Clinical
  name: Dilated cardiomyopathy
  description: >-
    Heart failure with reduced ejection fraction is the defining feature of
    PPCM, presenting with dyspnea, orthopnea, fatigue, and exercise intolerance.
  phenotype_term:
    preferred_term: Dilated cardiomyopathy
    term:
      id: HP:0001644
      label: Dilated cardiomyopathy
  evidence:
  - reference: PMID:37414337
    reference_title: "Peripartum cardiomyopathy: A review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Peripartum cardiomyopathy is a rare type of heart failure manifesting
      towards the end of pregnancy or in the months following delivery, in
      the absence of any other cause of heart failure
    explanation: >-
      Confirms heart failure as the defining clinical manifestation of PPCM.
  - reference: PMID:20675664
    reference_title: "Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It typically develops during the last month of, and up to 6 months
      after, pregnancy in women without known cardiovascular disease
    explanation: >-
      ESC position statement defines the temporal presentation of PPCM
      heart failure.
- category: Clinical
  name: Dyspnea
  description: >-
    Shortness of breath is the most common presenting symptom, often initially
    attributed to normal pregnancy.
  phenotype_term:
    preferred_term: Dyspnea
    term:
      id: HP:0002094
      label: Dyspnea
- category: Clinical
  name: Peripheral edema
  description: >-
    Lower extremity swelling occurs due to fluid overload from cardiac dysfunction,
    though it may be difficult to distinguish from normal pregnancy-related edema.
  phenotype_term:
    preferred_term: Peripheral edema
    term:
      id: HP:0012398
      label: Peripheral edema
- category: Clinical
  name: Left ventricular systolic dysfunction
  description: >-
    Reduced left ventricular ejection fraction (typically below 45%) detected
    by echocardiography is a diagnostic criterion for PPCM.
  phenotype_term:
    preferred_term: Reduced left ventricular ejection fraction
    term:
      id: HP:0012664
      label: Reduced left ventricular ejection fraction
- category: Clinical
  name: Fatigue
  description: >-
    Profound fatigue and exercise intolerance are common symptoms, reflecting
    decreased cardiac output.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Clinical
  name: Thromboembolism
  description: >-
    PPCM carries an elevated risk of thromboembolic events including deep vein
    thrombosis and stroke, due to the hypercoagulable state of pregnancy
    compounded by ventricular dysfunction and stasis.
  phenotype_term:
    preferred_term: Thromboembolism
    term:
      id: HP:0001907
      label: Thromboembolism
- category: Clinical
  name: Arrhythmia
  description: >-
    ECG and rhythm abnormalities are part of PPCM assessment. Cohort ECGs
    document sinus tachycardia, atrial fibrillation, ventricular ectopy, bundle
    branch block, ST/T changes, and review-level evidence notes ventricular
    tachyarrhythmias in severe left ventricular dysfunction.
  phenotype_term:
    preferred_term: Arrhythmia
    term:
      id: HP:0011675
      label: Arrhythmia
  evidence:
  - reference: PMID:30843220
    reference_title: Electrocardiographic findings in peripartum cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One woman was in atrial fibrillation, and all other subjects were in sinus rhythm; 45 (51%) had a normal sinus rhythm, 37 (42%) showed sinus tachycardia, and 5 (6%) showed sinus bradycardia. Ventricular ectopic beats were observed in 3 subjects.
    explanation: >-
      The IPAC cohort documents rhythm abnormalities including atrial
      fibrillation, sinus tachycardia, sinus bradycardia, and ventricular ectopy
      among women with PPCM.
  - reference: PMID:33791817
    reference_title: ECG and arrhythmias in peripartum cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Studies on the use of the wearable cardioverter-defibrillator in patients with PPCM show a substantial burden of ventricular tachyarrhythmias and sudden death in patients with severely reduced left ventricular function.
    explanation: >-
      This review supports ventricular tachyarrhythmias as a clinically relevant
      rhythm complication in severe PPCM.
genetic:
- name: TTN truncating variants
  gene_term:
    preferred_term: TTN
    term:
      id: hgnc:12403
      label: TTN
  association: >-
    Truncating variants in titin (TTN) are the most commonly identified genetic
    risk factor for PPCM, found in approximately 10-15% of cases.
  evidence:
  - reference: PMID:26735901
    reference_title: "Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      65% of variants occurred in TTN (in 10% of the patients,
      P = 2.7×10−10 for the comparison with the reference population).
      The great majority of these variants occurred in constitutively
      expressed exons and in the region encoding the A-band
    explanation: >-
      NEJM 2016 study identified TTN truncating variants in 10% of PPCM
      patients, predominantly in the A-band, establishing TTN as the most
      prevalent genetic predisposition.
  - reference: PMID:26735901
    reference_title: "Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the presence of TTN truncating variants was significantly correlated
      with a lower ejection fraction at 1-year follow-up (P=0.005)
    explanation: >-
      TTN truncating variants not only predispose to PPCM but also
      predict worse cardiac recovery, with lower ejection fraction at
      one year.
environmental:
- name: Pregnancy and peripartum hemodynamic stress
  description: >-
    Pregnancy imposes substantial hemodynamic stress including increased blood
    volume, increased cardiac output, and decreased systemic vascular resistance.
    The peripartum period represents the maximal hemodynamic load, which in
    susceptible individuals unmasks or triggers cardiomyopathy.
  evidence:
  - reference: PMID:22596155
    reference_title: "Cardiac angiogenic imbalance leads to peripartum cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This anti-angiogenic environment is accompanied by subclinical cardiac
      dysfunction, the extent of which correlates with circulating levels of
      sFLT1
    explanation: >-
      Human clinical data showing that the anti-angiogenic environment of
      late pregnancy causes subclinical cardiac dysfunction, supporting
      the peripartum period as a hemodynamic/hormonal stressor.
- name: Preeclampsia and hypertensive disorders
  description: >-
    Preeclampsia and gestational hypertension are significant risk factors for
    PPCM. The shared anti-angiogenic milieu (elevated sFlt1) mechanistically
    links these conditions.
  evidence:
  - reference: PMID:24013055
    reference_title: "The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The prevalence of PE, hypertensive disorders, and multiple gestations in women with PPCM is markedly higher than that in the general population"
    explanation: >-
      Meta-analysis of 22 studies demonstrates a markedly elevated prevalence
      of pre-eclampsia in PPCM cohorts compared to the general population.
  - reference: PMID:24013055
    reference_title: "The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These findings support the concept of a shared pathogenesis between PE and PPCM and highlight the need for awareness of the overlap between these 2 diseases"
    explanation: >-
      Supports a mechanistic link between preeclampsia and PPCM through
      shared anti-angiogenic pathogenesis.
- name: Multiparity and multiple gestations
  description: >-
    Multiple pregnancies and twin/higher-order gestations increase PPCM risk,
    likely through increased hemodynamic stress and elevated anti-angiogenic
    factor levels.
  evidence:
  - reference: PMID:22596155
    reference_title: "Cardiac angiogenic imbalance leads to peripartum cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In humans, the placenta in late gestation secretes VEGF inhibitors
      like soluble FLT1 (sFLT1), and this is accentuated by multiple
      gestation and pre-eclampsia
    explanation: >-
      Human clinical observation demonstrating that multiple gestation
      increases anti-angiogenic burden through elevated sFLT1,
      mechanistically linking multiple gestations to PPCM risk.
treatments:
- name: Standard heart failure therapy
  description: >-
    Guideline-directed medical therapy for heart failure with reduced ejection
    fraction, including ACE inhibitors (postpartum), beta-blockers, diuretics,
    and aldosterone antagonists.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:37414337
    reference_title: "Peripartum cardiomyopathy: A review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It includes standard pharmacological therapies for heart failure,
      within the safety restrictions for pregnancy and lactation
    explanation: >-
      Review confirms that standard heart failure pharmacotherapy is the
      foundation of PPCM management, with modifications for pregnancy
      and lactation safety.
- name: Bromocriptine
  description: >-
    Bromocriptine, a dopamine agonist that suppresses prolactin secretion,
    has been investigated as a targeted therapy for PPCM based on the 16-kDa
    prolactin pathogenesis hypothesis. Evidence from randomized trials suggests
    benefit in left ventricular recovery.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: bromocriptine
      term:
        id: CHEBI:3181
        label: bromocriptine
  target_mechanisms:
  - target: Oxidative stress and 16-kDa prolactin generation
    treatment_effect: INHIBITS
    description: >-
      Bromocriptine suppresses prolactin secretion, preventing cathepsin D
      cleavage of prolactin into the cardiotoxic 16-kDa fragment.
  evidence:
  - reference: PMID:20308616
    reference_title: "Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the addition of bromocriptine to standard heart failure therapy
      appeared to improve left ventricular ejection fraction and a composite
      clinical outcome in women with acute severe PPCM
    explanation: >-
      Proof-of-concept RCT showing bromocriptine added to standard therapy
      resulted in significantly greater LVEF recovery at 6 months.
  - reference: PMID:17289576
    reference_title: "A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Treatment with bromocriptine, an inhibitor of prolactin secretion,
      prevents the development of PPCM
    explanation: >-
      Seminal mouse model study demonstrating bromocriptine prevents PPCM
      by blocking prolactin secretion and its pathogenic 16-kDa cleavage
      product.
- name: Mechanical circulatory support
  description: >-
    In severe cases with cardiogenic shock or refractory heart failure,
    mechanical circulatory support (ventricular assist devices, ECMO) may
    be needed as bridge to recovery or transplantation.
  treatment_term:
    preferred_term: mechanical circulatory support
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: Cardiac transplantation
  description: >-
    Heart transplantation is considered for patients with severe, refractory
    PPCM who do not recover ventricular function despite optimal medical
    therapy and mechanical support.
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: MAXO:0010039
      label: organ transplantation
- name: Anticoagulation
  description: >-
    Anticoagulation is recommended for PPCM patients with severe left
    ventricular dysfunction (LVEF <35% in Europe, <30% in the US) due to
    increased thromboembolic risk. LMWH is preferred during pregnancy;
    warfarin may be used postpartum. Prophylactic anticoagulation is also
    advised when bromocriptine is used due to its prothrombotic effects.
  treatment_term:
    preferred_term: anticoagulant agent therapy
    term:
      id: MAXO:0000178
      label: anticoagulant agent therapy
clinical_trials:
- name: NCT05180773
  phase: PHASE_IV
  status: RECRUITING
  description: >-
    REBIRTH (Randomized Evaluation of Bromocriptine In Myocardial Recovery
    THerapy) is a phase 4, randomized, placebo-controlled trial evaluating
    bromocriptine therapy in 200 women newly diagnosed with PPCM within
    5 months postpartum. Primary endpoint is LVEF at 6 months.
  evidence:
  - reference: clinicaltrials:NCT05180773
    supports: SUPPORT
    snippet: >-
      The study will enroll 200 women newly diagnosed with peripartum
      cardiomyopathy within 5 months postpartum in a randomized placebo
      controlled trial of bromocriptine therapy to evaluate its impact on
      myocardial recovery and clinical outcomes
    explanation: >-
      Definitive phase 4 RCT designed to resolve the clinical question
      of whether bromocriptine improves myocardial recovery in PPCM.
epidemiology:
- name: Geographic and ethnic variation
  description: >-
    PPCM incidence varies markedly by geography and ethnicity, with the
    highest rates in sub-Saharan Africa and Haiti (1 in 100-300) and lower
    rates in Europe and the United States (1 in 1000-4000). Women of African
    descent are disproportionately affected.
  evidence:
  - reference: PMID:26735901
    reference_title: "Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The incidence varies from 1 in 100 to 1 in 300 in geographic hot
      spots, including Nigeria and Haiti, to 1 in 1000 to 1 in 4000 in
      Europe and the United States
    explanation: >-
      NEJM study documents the striking geographic variation in PPCM
      incidence.
- name: Prognosis and recovery
  description: >-
    PPCM carries a mortality rate of up to 10%, but over half of affected
    women recover left ventricular function within a year of diagnosis.
    Subsequent pregnancies carry a high relapse risk.
  evidence:
  - reference: PMID:37414337
    reference_title: "Peripartum cardiomyopathy: A review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Peripartum cardiomyopathy carries a high mortality rate of up to 10%
      and a high risk of relapse in subsequent pregnancies, but over half
      of women present normalization of LV function within a year of
      diagnosis
    explanation: >-
      Review summarizing key prognostic data for PPCM including mortality,
      recovery rates, and relapse risk.
datasets:

📚

References & Deep Research

Deep Research

2

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 31 citations 2026-05-04T12:49:31.719401

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Peripartum Cardiomyopathy
MONDO ID: (if available)
Category: Complex

Research Objectives

Please provide a comprehensive research report on Peripartum Cardiomyopathy covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Disease Characteristics Report: Peripartum Cardiomyopathy (PPCM)

Executive summary

Peripartum cardiomyopathy (PPCM) is an idiopathic cardiomyopathy presenting as new-onset heart failure (HF) with left-ventricular (LV) systolic dysfunction, typically in late pregnancy or in the months postpartum, and is defined in most contemporary sources by LVEF <45% after exclusion of alternative causes. Incidence varies markedly by geography (from ~1:300 in Haiti to ~1:20,000 in Japan), with strong associations with hypertensive disorders of pregnancy and ancestry-associated disparities. A leading contemporary mechanistic framework is a “two-hit” vasculo-hormonal/angiogenic model implicating oxidative stress–dependent cleavage of prolactin to a pathogenic 16-kDa fragment and placental anti-angiogenic signaling (sFlt-1) with reduced VEGF/PGC-1α signaling. Clinical management largely follows guideline-directed HFrEF therapy tailored to pregnancy/lactation, with bromocriptine as the most widely discussed disease-targeted therapy (evidence suggests improved LVEF and higher odds of recovery but uncertain mortality benefit). Major knowledge gaps remain in standardized biomarker validation, high-quality randomized trials, and comprehensive genetics and epidemiology in diverse populations. (sigauke2024peripartumcardiomyopathya pages 1-2, sigauke2024peripartumcardiomyopathya pages 5-7, iannaccone2024diagnosisandmanagement pages 1-2, kumar2023prolactininhibitionin pages 4-6)

1. Disease information

1.1 What is PPCM?

Definition (current understanding): PPCM is an idiopathic cardiomyopathy characterized by de novo HF due to new LV systolic dysfunction occurring toward the end of pregnancy or in the months after delivery, typically defined by LVEF <45%, after excluding other causes of cardiomyopathy and HF. (iannaccone2024diagnosisandmanagement pages 1-2, sigauke2024peripartumcardiomyopathya pages 1-2, sigauke2024peripartumcardiomyopathya pages 2-4)

Common diagnostic criteria referenced in contemporary reviews: - NHLBI (2000) criteria include (i) HF in last month of pregnancy or within 5 months postpartum, (ii) no identifiable cause, (iii) no recognizable heart disease before last pregnancy month, and (iv) echo evidence of LV dysfunction: LVEF <45%, fractional shortening <30%, and/or LVEDD >2.7 cm/m². (sigauke2024peripartumcardiomyopathya pages 1-2) - ESC simplified definition (used clinically): idiopathic cardiomyopathy with HF from LV systolic dysfunction toward the end of pregnancy or months postpartum, typically LVEF <45%. (sigauke2024peripartumcardiomyopathya pages 2-4)

Synonyms/alternate names (used in literature): peripartum cardiomyopathy, postpartum cardiomyopathy, pregnancy-associated cardiomyopathy (overlapping usage in reviews; operationally PPCM is the dominant term). (sigauke2024peripartumcardiomyopathya pages 1-2, sigauke2024peripartumcardiomyopathya pages 2-4)

1.2 Key identifiers (ICD/MeSH/MONDO/Orphanet/OMIM)

The retrieved primary/review texts did not contain explicit ICD-10/ICD-11, MeSH, MONDO, Orphanet, or OMIM identifiers in the extracted sections; therefore these identifiers cannot be reliably reported from the present evidence set. (sigauke2024peripartumcardiomyopathya pages 1-2, iannaccone2024diagnosisandmanagement pages 1-2)

1.3 Evidence source type

The information synthesized here is derived from aggregated disease-level resources (peer-reviewed narrative reviews, systematic reviews/meta-analyses, and registry/trial summaries) and one retrospective cohort study. (sigauke2024peripartumcardiomyopathya pages 1-2, iannaccone2024diagnosisandmanagement pages 1-2, noll2024breastfeedinginpatients pages 1-2, kumar2023prolactininhibitionin pages 4-6)

2. Etiology

2.1 Disease causal factors (multifactorial “two-hit” model)

Contemporary sources emphasize that PPCM is multifactorial. A widely discussed mechanistic framework is a vasculo-hormonal/angiogenic “two-hit” model in which pregnancy-related hormonal/vascular stress triggers HF in susceptible individuals (including genetic susceptibility). (sigauke2024peripartumcardiomyopathya pages 2-4, sigauke2024peripartumcardiomyopathya pages 5-7, sigauke2024peripartumcardiomyopathya pages 4-5)

2.2 Risk factors (with quantified estimates where available)

Quantified and repeatedly cited risks include: - African American/Black ancestry: “African Americans are 3–16 times more likely to develop the disease in comparison to white women.” (Iannaccone 2024; publication date Sep 2024; DOI URL: https://doi.org/10.1016/j.ijcchd.2024.100530) (iannaccone2024diagnosisandmanagement pages 1-2). Another review excerpt reports ~4× higher frequency among African-American women. (laskowska2026peripartumcardiomyopathy–whatisa pages 3-5) - Hypertensive disorders of pregnancy: gestational hypertension or pre-eclampsia associated with ~3-fold increased risk. (iannaccone2024diagnosisandmanagement pages 1-2) - Advanced maternal age: one cited estimate reports 10-fold higher risk for women >40 vs <20 years. (iannaccone2024diagnosisandmanagement pages 1-2) - Multiple gestation: present in 7–14.5% of cases in reported series. (iannaccone2024diagnosisandmanagement pages 1-2)

Additional commonly cited risk factors (often reported qualitatively or without pooled effect size in the retrieved excerpts) include: multiparity, family history, infertility treatment, anemia/malnutrition, obesity/diabetes, smoking/alcohol/drug use, low BMI, selenium deficiency, and prolonged beta-agonist tocolysis. (sigauke2024peripartumcardiomyopathya pages 4-5, iannaccone2024diagnosisandmanagement pages 1-2)

2.3 Protective factors

Protective genetic or environmental factors were not identified with quantifiable effect sizes in the retrieved evidence excerpts. (sigauke2024peripartumcardiomyopathya pages 1-2, iannaccone2024diagnosisandmanagement pages 1-2)

2.4 Gene–environment interaction

A specific conceptual gene–environment interaction described is that pregnancy-associated vascular/hormonal stress can unmask disease in genotype-positive/phenotype-negative women (a “two-hit” hypothesis). The comprehensive review notes that >90% of variant carriers do not develop PPCM, supporting the need for additional triggers beyond genotype alone. (sigauke2024peripartumcardiomyopathya pages 5-7)

3. Phenotypes

3.1 Clinical phenotypes (symptoms/signs)

Typical HF presentation: fatigue, dyspnea, orthopnea, and congestion/peripheral edema, which may be mistaken for physiologic pregnancy changes—necessitating high suspicion. (yusuf2025advancingourunderstanding pages 1-2, sigauke2024peripartumcardiomyopathya pages 7-8)

Electrocardiographic phenotype: ECG abnormalities are common (>90% in the cited review), including sinus tachycardia, LBBB, atrial fibrillation, T-wave inversion, and prolonged QTc. (sigauke2024peripartumcardiomyopathya pages 5-7)

Time of onset: most cases are postpartum: ~75% in the first month postpartum and ~45% in the first week. (sigauke2024peripartumcardiomyopathya pages 2-4)

3.2 Phenotype characteristics and frequencies

Onset window: classic definition is last pregnancy month to 5 months postpartum, but broader/time-independent definitions exist. (iannaccone2024diagnosisandmanagement pages 1-2, sigauke2024peripartumcardiomyopathya pages 1-2)
Severity/progression: ranges from mild HF to cardiogenic shock; severe cases can require mechanical circulatory support. (laskowska2026peripartumcardiomyopathycurrent pages 19-20, iannaccone2024diagnosisandmanagement pages 4-5)

3.3 Quality of life impact

Quality-of-life (QoL) burden is implicit through HF symptoms and hospitalization risk; specific instrumented QoL statistics were not extracted from the retrieved snippets (though QoL endpoints appear in trial designs). (NCT02590601 chunk 1)

3.4 Suggested HPO terms (examples)

A structured list of phenotype ontology suggestions is provided in the ontology artifact. (artifact-01)

4. Genetic / molecular information

4.1 Causal/susceptibility genes and estimated contribution

Genetic predisposition is increasingly recognized; a comprehensive 2024 review states that genetics may explain up to ~15% of PPCM cases, with TTN truncating variants a predominant contributor; other implicated genes include MYH, MYBPC3, LMNA, and SCN5A. (Sigauke 2024; Sep 2024; https://doi.org/10.1007/s10741-024-10435-5) (sigauke2024peripartumcardiomyopathya pages 5-7)

4.2 Variant types and functional consequences

The retrieved evidence specifically highlights TTN truncating variants as predominant. Detailed PPCM-specific variant nomenclature, allele frequencies (gnomAD), and functional validation results were not present in the extracted PPCM evidence snippets. (sigauke2024peripartumcardiomyopathya pages 5-7)

4.3 Modifier genes / epigenetics / chromosomal abnormalities

These were not described with specific loci or validated epigenetic signatures in the extracted evidence. (sigauke2024peripartumcardiomyopathya pages 1-2, sigauke2024peripartumcardiomyopathya pages 5-7)

5. Environmental information

Environmental/lifestyle contributors are reported largely as risk factor associations (smoking, alcohol/drug use, malnutrition, selenium deficiency, low BMI). Specific toxicant/pathogen triggers were not supported with direct evidence in the extracted texts. (sigauke2024peripartumcardiomyopathya pages 4-5, iannaccone2024diagnosisandmanagement pages 1-2)

6. Mechanism / pathophysiology

6.1 Core mechanistic framework (causal chain)

A leading contemporary mechanism is a vasculo-hormonal/angiogenic two-hit model: 1) Oxidative stress/STAT3 axis: STAT3-dependent reduction in MnSOD leads to increased ROS, activation of cathepsin D, and cleavage of 23-kDa prolactin into a pathogenic 16-kDa fragment (vasoinhibin). This fragment promotes endothelial injury and downstream cardiomyocyte dysfunction, with an emphasized role for NF-κB and endothelial microRNA-146a. (sigauke2024peripartumcardiomyopathya pages 2-4, sigauke2024peripartumcardiomyopathya pages 4-5) 2) Placental angiogenic imbalance: elevation of anti-angiogenic sFlt-1 with reduced VEGF and suppressed PGC-1α signaling contributes to impaired angiogenesis/endothelial dysfunction and myocardial injury. sFlt-1 is linked to more severe disease and worse prognosis. (sigauke2024peripartumcardiomyopathya pages 2-4, sigauke2024peripartumcardiomyopathya pages 4-5)

Additional mechanistic themes include inflammation/autoimmunity, altered pregnancy hemodynamics (volume overload), metabolic changes, and other hormonal mediators (e.g., decreased relaxin-2; activin A as an emerging biomarker). (sigauke2024peripartumcardiomyopathya pages 4-5)

6.2 Suggested GO terms / CL terms / UBERON structures

Suggested ontology mapping across phenotypes, biological processes, cell types, and anatomical structures is provided in artifact-01. (artifact-01)

7. Anatomical structures affected

7.1 Primary organ/system involvement

Primary pathology involves the heart, particularly the left ventricle and myocardium, with vascular/endothelial involvement as a central mechanistic node. (iannaccone2024diagnosisandmanagement pages 1-2, sigauke2024peripartumcardiomyopathya pages 2-4, sigauke2024peripartumcardiomyopathya pages 7-8)

7.2 Pregnancy-associated structure

The placenta is implicated in pathophysiology via anti-angiogenic signaling (e.g., sFlt-1). (sigauke2024peripartumcardiomyopathya pages 2-4, iannaccone2024diagnosisandmanagement pages 1-2)

Ontology suggestions for UBERON structures are listed in artifact-01. (artifact-01)

8. Temporal development

8.1 Onset

Classic onset window is last pregnancy month through 5 months postpartum (NHLBI criterion), but more recent discussions broaden timing and may consider earlier or later presentations. (sigauke2024peripartumcardiomyopathya pages 1-2, iannaccone2024diagnosisandmanagement pages 1-2)

8.2 Progression and recovery

A 2024 review reports that recovery of LVEF occurs in most patients (~76%), usually within 6 months. (iannaccone2024diagnosisandmanagement pages 4-5)

9. Inheritance and population

9.1 Epidemiology

Incidence varies markedly by region and ancestry: - Global incidence is commonly cited around ~1 per 2,000 deliveries, but can be ~1:300 in Haiti and ~1:20,000 in Japan; very high rates have been reported in parts of Nigeria (e.g., ~1:100 in Kano). (sigauke2024peripartumcardiomyopathya pages 1-2, iannaccone2024diagnosisandmanagement pages 1-2) - South African cohorts report ~1:1,000 and ~1:3,000 live births. (sigauke2024peripartumcardiomyopathya pages 2-4)

9.2 Demographic disparities

African American race has substantially higher risk (3–16× versus White women), and recovery rates may be lower in Afro-American women (~45% recovery in a cited estimate). (iannaccone2024diagnosisandmanagement pages 1-2, iannaccone2024diagnosisandmanagement pages 4-5)

9.3 Inheritance pattern

PPCM likely spans a spectrum from sporadic to familial susceptibility overlapping with dilated cardiomyopathy genetics; explicit Mendelian inheritance patterns for PPCM per se were not provided in the extracted evidence. (sigauke2024peripartumcardiomyopathya pages 5-7)

10. Diagnostics

10.1 Core diagnostic workflow (real-world)

Echocardiography is the preferred initial imaging modality (safe and widely available in pregnancy/lactation) and is central to diagnosis, risk stratification, and follow-up. (sigauke2024peripartumcardiomyopathya pages 7-8)
Natriuretic peptides are key adjunct diagnostics with strong negative predictive value for HF: BNP <100 pg/mL, NT-proBNP <300 pg/mL, MR-proANP <120 pmol/L (as thresholds with high negative predictive value in a cited review). (sigauke2024peripartumcardiomyopathya pages 5-7)
ECG abnormalities are common and can provide prognostic signals (e.g., sinus tachycardia and prolonged QTc associated with worse prognosis in the cited review). (sigauke2024peripartumcardiomyopathya pages 5-7, sigauke2024peripartumcardiomyopathya pages 7-8)

10.2 Biomarkers (investigational)

Multiple candidate biomarkers remain under study (microRNA-146a, cathepsin D, 16-kDa prolactin fragment, interferon-γ, ADMA, sFlt-1, sST2, Gal-3, GDF-15, adrenomedullin, long noncoding RNAs, heat shock proteins), but diagnostic thresholds and clinical specificity are not established in the extracted evidence. (sigauke2024peripartumcardiomyopathya pages 5-7, sigauke2024peripartumcardiomyopathya pages 7-8)

10.3 Prognostic biomarker statistic

In one cohort cited by the comprehensive review, NT-proBNP >900 pg/mL at diagnosis predicted poor LV recovery. (sigauke2024peripartumcardiomyopathya pages 5-7)

11. Outcome / prognosis

11.1 Maternal outcomes

PPCM has substantial morbidity and mortality. - Mortality estimates in the comprehensive review include reported mortality 7–15%. (sigauke2024peripartumcardiomyopathya pages 1-2) - Severe disease can require mechanical circulatory support and transplant consideration; LV/BiVAD required in up to 7% (per 2024 management review excerpt). (iannaccone2024diagnosisandmanagement pages 4-5)

11.2 Subsequent pregnancy outcomes (2024 meta-analysis)

A 2024 systematic review/meta-analysis of subsequent pregnancy (SSP) reported: - Total 487 subsequent pregnancies. (wijayanto2024outcomesofsubsequent pages 1-1) - Mortality in SSP ranged from 0% to 55.5% across studies. (wijayanto2024outcomesofsubsequent pages 1-1, wijayanto2024outcomesofsubsequent pages 3-4) - Persistent LV dysfunction was associated with increased mortality (OR 13.17; 95% CI 1.54–112.28; p=0.02) and lower LVEF (MD −12.88; 95% CI −21.67 to −4.09; p=0.004). (Wijayanto 2024; Apr 2024; https://doi.org/10.1136/openhrt-2024-002626) (wijayanto2024outcomesofsubsequent pages 1-1)

11.3 Prognostic factors

The extracted evidence emphasizes pre-pregnancy/presentation LVEF as a major determinant of outcomes and relapse risk (including in subsequent pregnancies). (laskowska2026peripartumcardiomyopathy–whatisa pages 16-17, iannaccone2024diagnosisandmanagement pages 4-5, wijayanto2024outcomesofsubsequent pages 1-1)

12. Treatment

12.1 Guideline-directed HF therapy (application in practice)

Treatment largely follows HFrEF guidelines, modified for pregnancy and lactation safety. Pregnancy/postpartum medication selection is commonly presented as an algorithm (see Figure in the 2024 comprehensive review). (iannaccone2024diagnosisandmanagement pages 4-5, sigauke2024peripartumcardiomyopathya media 4d9eef0c)

12.2 Bromocriptine / prolactin inhibition (evidence and interpretation)

Evidence base (2023 meta-analysis): A systematic review/meta-analysis (10 studies; 749 patients; including RCTs and cohorts) found bromocriptine plus GDMT was associated with improved LVEF and higher odds of recovery: - Follow-up LVEF higher with bromocriptine: pooled mean difference 12.56% (cohorts; 95% CI 5.84–19.28) and 14.25% (RCTs; 95% CI 0.61–27.89). (kumar2023prolactininhibitionin pages 4-6) - Higher odds of LV recovery: pooled OR 3.55 (95% CI 1.39–9.10). (kumar2023prolactininhibitionin pages 4-6) - No statistically significant mortality reduction in pooled analyses (e.g., RCT pRR 0.53, 95% CI 0.26–1.07). (kumar2023prolactininhibitionin pages 4-6)

Clinical implementation details (review-level guidance): Bromocriptine 2.5 mg twice daily is suggested for 8 weeks in moderate/severe PPCM and for 1 week in mild cases; due to prothrombotic concerns, at least prophylactic anticoagulation is advised when bromocriptine is used. (iannaccone2024diagnosisandmanagement pages 4-5)

12.3 Anticoagulation

Guidelines summarized in a 2024 management review recommend anticoagulation in severe LV dysfunction (Europe: LVEF <35%; US: LVEF <30%). LMWH is preferred during pregnancy; both LMWH and warfarin may be used during lactation in appropriate contexts; DOACs are contraindicated in pregnancy and breastfeeding. (iannaccone2024diagnosisandmanagement pages 4-5)

12.4 Mechanical support and transplant

Severe cases may require ECMO/LVAD/BiVAD as bridge-to-recovery or transplant; the 2024 management review excerpt states LV/BiVAD may be required in up to 7%. (laskowska2026peripartumcardiomyopathycurrent pages 19-20, iannaccone2024diagnosisandmanagement pages 4-5)

12.5 Breastfeeding and real-world counseling

A 2024 retrospective cohort study addressing lactation outcomes found no significant association between breastfeeding and recovery: - Quote (abstract): “Of 220 patients with confirmed PPCM, lactation status was known definitively in 54 patients; of these, 18 (33%) had breastfed for at least 6 weeks and 36 (67%) did not breastfeed.” (Noll 2024; Oct 2024; https://doi.org/10.1186/s13006-024-00673-6) (noll2024breastfeedinginpatients pages 1-2) - Quote (abstract): “In this retrospective cohort, lactation was not associated with lower rates of myocardial recovery.” (noll2024breastfeedinginpatients pages 1-2) - Counseling gap (abstract): “Of the 34 survey respondents, 62% were told not to breastfeed… and none were encouraged to breastfeed.” (noll2024breastfeedinginpatients pages 1-2)

12.6 MAXO term suggestions

Intervention ontology suggestions (e.g., bromocriptine therapy, anticoagulation, beta-blocker therapy, ACE inhibitor postpartum, diuretic therapy, mechanical circulatory support) are listed in artifact-01. (artifact-01)

13. Prevention

No validated primary prevention intervention is established in the extracted evidence set; prevention is largely risk-factor recognition (e.g., hypertensive disorders) and early detection in symptomatic patients. (iannaccone2024diagnosisandmanagement pages 1-2, sigauke2024peripartumcardiomyopathya pages 7-8)

14. Other species / natural disease

No naturally occurring non-human species disease analogs were identified in the extracted evidence set. (sigauke2024peripartumcardiomyopathya pages 1-2)

15. Model organisms

Mechanistic support for the STAT3/oxidative stress/prolactin model is described in relation to STAT3 knock-out mouse models in the 2024 comprehensive review excerpt, but detailed model descriptions (strain, phenotype penetrance) were not extracted in the provided snippets. (sigauke2024peripartumcardiomyopathya pages 2-4)

Recent developments and latest research (2023–2024 prioritized)

1) Broader biomarker landscape and diagnostic thresholds: The 2024 comprehensive review highlights natriuretic peptide thresholds for high negative predictive value (BNP <100 pg/mL; NT-proBNP <300 pg/mL; MR-proANP <120 pmol/L) and reports NT-proBNP >900 pg/mL as a predictor of poor LV recovery in one cohort, while cataloging emerging molecular markers (miR-146a, sFlt-1, sST2, Gal-3, GDF-15, etc.). (sigauke2024peripartumcardiomyopathya pages 5-7)

2) Genetics as an enabling direction for risk prediction: The same 2024 review emphasizes that genetics may explain up to ~15% of PPCM and highlights TTN truncating variants with overlap to dilated cardiomyopathy genes, reinforcing the two-hit pregnancy-trigger model. (sigauke2024peripartumcardiomyopathya pages 5-7)

3) Bromocriptine evidence synthesis: A 2023 systematic review/meta-analysis found improved LVEF and higher odds of recovery with bromocriptine but no clear mortality benefit, highlighting ongoing uncertainty and the need for adequately powered trials. (kumar2023prolactininhibitionin pages 4-6)

4) Breastfeeding outcomes and counseling (real-world implementation): 2024 retrospective data suggest lactation is not associated with worse recovery, while documenting a high rate of discouraging counseling (62% told not to breastfeed). (noll2024breastfeedinginpatients pages 1-2)

5) Subsequent pregnancy outcomes quantified (2024): persistent LV dysfunction substantially elevates mortality odds in subsequent pregnancy (OR 13.17). (wijayanto2024outcomesofsubsequent pages 1-1)

Current applications and real-world implementations

Clinical management algorithms

The 2024 comprehensive review includes a pharmacologic management algorithm (Figure 3) that distinguishes therapy during pregnancy versus postpartum and includes modern HFrEF classes and bromocriptine considerations. (sigauke2024peripartumcardiomyopathya media 4d9eef0c)

Anticoagulation in practice

Anticoagulation thresholds based on LVEF (<35% Europe; <30% US) and contraindications to DOACs in pregnancy/breastfeeding reflect real-world implementation constraints. (iannaccone2024diagnosisandmanagement pages 4-5)

Expert opinions / authoritative analysis (from reviews)

Reviews emphasize PPCM remains challenging to diagnose because symptoms overlap with normal pregnancy changes, requiring high clinical suspicion and systematic evaluation (echo, ECG, biomarkers). (sigauke2024peripartumcardiomyopathya pages 7-8, sigauke2024peripartumcardiomyopathya pages 5-7)
Bromocriptine is frequently described as the only targeted drug but with insufficient high-quality evidence for universal recommendation; authors note need for better randomized data. (iannaccone2024diagnosisandmanagement pages 1-2, iannaccone2024diagnosisandmanagement pages 5-6)

Relevant clinical trials (ClinicalTrials.gov)

REBIRTH (NCT05180773) – Recruiting

Title: Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
Start date: 2022-07-27; primary completion: 2026-06-30; study completion: 2028-12-31
Design: Phase 4, quadruple-masked, randomized placebo-controlled
Intervention: bromocriptine for 8 weeks (2.5 mg BID ×2 weeks then 2.5 mg daily ×6 weeks) + GDMT; anticoagulation-matching includes rivaroxaban 10 mg daily for 8 weeks in those not otherwise anticoagulated
Primary endpoint: LVEF at 6 months (echo; adjusted for baseline)
URL: https://clinicaltrials.gov/study/NCT05180773 (NCT05180773 chunk 1)

NCT00998556 – Completed

Start: June 2010; primary completion March 2016; completion August 2016
Phase 2, randomized, parallel, open-label; n=64
Eligibility includes LV ejection fraction ≤35% within 5 months postpartum
Primary endpoint: change in LVEF baseline to 6 months by MRI and echo
URL: https://clinicaltrials.gov/study/NCT00998556 (NCT00998556 chunk 1)

BRO-HF (NCT02590601) – Withdrawn

Phase 3 Bayesian randomized registry trial; withdrawn for insufficient enrollment
Arms: bromocriptine + GDMT vs GDMT
Primary endpoint: 1-year MACE composite; secondary includes proportion with LVEF ≥54% at 6 months
URL: https://clinicaltrials.gov/study/NCT02590601 (NCT02590601 chunk 1)

Structured evidence tables (for knowledge-base population)

Domain	Key finding	Quantitative detail	Source (author, year, journal)	URL/DOI
Definition/diagnostic criteria	PPCM is de novo/idiopathic heart failure with new LV systolic dysfunction in late pregnancy or postpartum; diagnosis is by exclusion, and LV dilation may be absent (sigauke2024peripartumcardiomyopathya pages 1-2, iannaccone2024diagnosisandmanagement pages 1-2)	LVEF <45%; older criteria also include M-mode fractional shortening <30% or LV end-diastolic dimension >2.7 cm/m² (sigauke2024peripartumcardiomyopathya pages 1-2, sigauke2024peripartumcardiomyopathya pages 2-4)	Sigauke et al., 2024, Heart Failure Reviews; Iannaccone et al., 2024, Int J Cardiol Congenital Heart Disease	https://doi.org/10.1007/s10741-024-10435-5; https://doi.org/10.1016/j.ijcchd.2024.100530
Definition/timing	Classic diagnostic window is last month of pregnancy to 5 months postpartum, though broader/time-independent definitions are now discussed (sigauke2024peripartumcardiomyopathya pages 1-2, iannaccone2024diagnosisandmanagement pages 1-2)	~19% diagnosed in final pregnancy month; ~75% within first month postpartum; ~45% within first postpartum week (sigauke2024peripartumcardiomyopathya pages 2-4)	Sigauke et al., 2024, Heart Failure Reviews; Iannaccone et al., 2024, Int J Cardiol Congenital Heart Disease	https://doi.org/10.1007/s10741-024-10435-5; https://doi.org/10.1016/j.ijcchd.2024.100530
Incidence/geographic variation	Global incidence is highly variable, with major geographic and ancestry-associated differences (sigauke2024peripartumcardiomyopathya pages 1-2, iannaccone2024diagnosisandmanagement pages 1-2)	Approx. 1:2,000 globally; reported 1:300 in Haiti, 1:20,000 in Japan, ~1:4,025 in the U.S., and up to 1:100 in Kano, Nigeria (sigauke2024peripartumcardiomyopathya pages 1-2)	Sigauke et al., 2024, Heart Failure Reviews; Iannaccone et al., 2024, Int J Cardiol Congenital Heart Disease	https://doi.org/10.1007/s10741-024-10435-5; https://doi.org/10.1016/j.ijcchd.2024.100530
Incidence/geographic variation	South African cohorts also illustrate substantial regional burden (sigauke2024peripartumcardiomyopathya pages 2-4)	1:1,000 and 1:3,000 live births in South African cohorts (sigauke2024peripartumcardiomyopathya pages 2-4)	Sigauke et al., 2024, Heart Failure Reviews	https://doi.org/10.1007/s10741-024-10435-5
Risk factors	African American/Black race is a major risk factor (iannaccone2024diagnosisandmanagement pages 1-2, laskowska2026peripartumcardiomyopathy–whatisa pages 3-5)	African Americans are 3–16 times more likely to develop PPCM than White women; PPCM is ~4× more common in African-American women in another review (iannaccone2024diagnosisandmanagement pages 1-2, laskowska2026peripartumcardiomyopathy–whatisa pages 3-5)	Iannaccone et al., 2024, Int J Cardiol Congenital Heart Disease; Laskowska, 2026, review excerpt	https://doi.org/10.1016/j.ijcchd.2024.100530
Risk factors	Hypertensive disorders of pregnancy are strongly associated with PPCM (iannaccone2024diagnosisandmanagement pages 1-2, sigauke2024peripartumcardiomyopathya pages 4-5)	Gestational hypertension/preeclampsia associated with ~3-fold increased risk; in one meta-analysis cited by Iannaccone et al., preeclampsia was present in 22% and hypertensive disorders in 97% of cases (iannaccone2024diagnosisandmanagement pages 1-2)	Iannaccone et al., 2024, Int J Cardiol Congenital Heart Disease; Sigauke et al., 2024, Heart Failure Reviews	https://doi.org/10.1016/j.ijcchd.2024.100530; https://doi.org/10.1007/s10741-024-10435-5
Risk factors	Advanced maternal age increases risk (iannaccone2024diagnosisandmanagement pages 1-2, sigauke2024peripartumcardiomyopathya pages 2-4)	10-fold higher risk for women >40 vs <20 years; registry mean age ~28.9–33 years, with higher risk at <20 and >35 years (iannaccone2024diagnosisandmanagement pages 1-2, sigauke2024peripartumcardiomyopathya pages 2-4)	Iannaccone et al., 2024, Int J Cardiol Congenital Heart Disease; Sigauke et al., 2024, Heart Failure Reviews	https://doi.org/10.1016/j.ijcchd.2024.100530; https://doi.org/10.1007/s10741-024-10435-5
Risk factors	Multiple gestation is a recurrently reported risk factor (iannaccone2024diagnosisandmanagement pages 1-2, sigauke2024peripartumcardiomyopathya pages 4-5)	Reported in 7–14.5% of cases (iannaccone2024diagnosisandmanagement pages 1-2)	Iannaccone et al., 2024, Int J Cardiol Congenital Heart Disease; Sigauke et al., 2024, Heart Failure Reviews	https://doi.org/10.1016/j.ijcchd.2024.100530; https://doi.org/10.1007/s10741-024-10435-5
Risk factors	Additional reported risk factors include multiparity, family history, infertility treatment, anemia/malnutrition, obesity/diabetes, smoking, alcohol/drug use, low BMI, and prolonged beta-agonist tocolysis (sigauke2024peripartumcardiomyopathya pages 4-5, laskowska2026peripartumcardiomyopathycurrent pages 4-5, iannaccone2024diagnosisandmanagement pages 1-2)	Quantification not consistently provided in the snippets; risk factor lists recur across reviews (sigauke2024peripartumcardiomyopathya pages 4-5, laskowska2026peripartumcardiomyopathycurrent pages 4-5, iannaccone2024diagnosisandmanagement pages 1-2)	Sigauke et al., 2024, Heart Failure Reviews; Laskowska, 2026, review excerpt; Iannaccone et al., 2024, Int J Cardiol Congenital Heart Disease	https://doi.org/10.1007/s10741-024-10435-5; https://doi.org/10.1016/j.ijcchd.2024.100530
Biomarkers/diagnostics	Natriuretic peptides are central diagnostic biomarkers with strong rule-out value (sigauke2024peripartumcardiomyopathya pages 5-7)	BNP <100 pg/mL, NT-proBNP <300 pg/mL, MR-proANP <120 pmol/L have high negative predictive value (sigauke2024peripartumcardiomyopathya pages 5-7)	Sigauke et al., 2024, Heart Failure Reviews	https://doi.org/10.1007/s10741-024-10435-5
Biomarkers/prognosis	Higher NT-proBNP at diagnosis predicts worse recovery (sigauke2024peripartumcardiomyopathya pages 5-7)	NT-proBNP >900 pg/mL predicted poor LV recovery in one cohort (sigauke2024peripartumcardiomyopathya pages 5-7)	Sigauke et al., 2024, Heart Failure Reviews	https://doi.org/10.1007/s10741-024-10435-5
Biomarkers/mechanistic candidates	Candidate molecular biomarkers under study include prolactin-axis, angiogenic, inflammatory, fibrosis, and RNA markers (sigauke2024peripartumcardiomyopathya pages 5-7, sigauke2024peripartumcardiomyopathya pages 7-8)	Reported candidates include microRNA-146a, cathepsin D, 16-kDa prolactin/vasoinhibin, sFlt1, sST2, Gal-3, GDF-15, ADM, interferon-γ, ADMA, long noncoding RNA, and heat-shock proteins; no validated clinical thresholds given in snippets (sigauke2024peripartumcardiomyopathya pages 5-7, sigauke2024peripartumcardiomyopathya pages 7-8)	Sigauke et al., 2024, Heart Failure Reviews	https://doi.org/10.1007/s10741-024-10435-5
Genetics	Genetic predisposition likely explains a minority but important subset of PPCM, fitting a “two-hit” model where pregnancy stress unmasks latent susceptibility (sigauke2024peripartumcardiomyopathya pages 5-7, sigauke2024peripartumcardiomyopathya pages 2-4)	Genetics may explain up to ~15% of cases; >90% of variant carriers do not develop PPCM, implying additional triggers (sigauke2024peripartumcardiomyopathya pages 5-7)	Sigauke et al., 2024, Heart Failure Reviews	https://doi.org/10.1007/s10741-024-10435-5
Genetics	TTN truncating variants are the predominant implicated genetic contributors; other cardiomyopathy genes are also reported (sigauke2024peripartumcardiomyopathya pages 5-7, sigauke2024peripartumcardiomyopathya pages 4-5)	Genes named in snippets: TTN (predominant), MYH, MYBPC3, LMNA, SCN5A; broader phrasing also notes sarcomeric/cytoskeletal genes linked to familial DCM/PPCM susceptibility (sigauke2024peripartumcardiomyopathya pages 5-7, sigauke2024peripartumcardiomyopathya pages 4-5)	Sigauke et al., 2024, Heart Failure Reviews	https://doi.org/10.1007/s10741-024-10435-5

Table: This table summarizes evidence-supported facts on peripartum cardiomyopathy definition, epidemiology, risk factors, biomarkers, and genetics. It is designed as a compact, citable artifact for rapid knowledge-base population.

Category	Suggested term label	Ontology (HPO/GO/CL/UBERON/MAXO)	Term ID (if known; otherwise leave blank)	Evidence/justification (brief)	Cited sources
Phenotype	Dyspnea	HPO	HP:0002094	PPCM commonly presents with heart-failure symptoms including dyspnea in late pregnancy/postpartum.	(yusuf2025advancingourunderstanding pages 1-2, iannaccone2024diagnosisandmanagement pages 1-2)
Phenotype	Orthopnea	HPO	HP:0002092	Orthopnea is listed among typical HF manifestations in PPCM reviews.	(yusuf2025advancingourunderstanding pages 1-2)
Phenotype	Edema	HPO	HP:0000969	Peripheral edema/congestion is a frequent presenting sign of PPCM-related HF.	(yusuf2025advancingourunderstanding pages 1-2, sigauke2024peripartumcardiomyopathya pages 7-8)
Phenotype	Left ventricular systolic dysfunction	HPO	HP:0005162	Core diagnostic feature of PPCM is new LV systolic dysfunction.	(iannaccone2024diagnosisandmanagement pages 1-2, sigauke2024peripartumcardiomyopathya pages 1-2)
Phenotype	Reduced left ventricular ejection fraction	HPO		PPCM is generally defined by LVEF <45%; reduced LVEF is central to diagnosis/prognosis.	(iannaccone2024diagnosisandmanagement pages 1-2, sigauke2024peripartumcardiomyopathya pages 1-2, sigauke2024peripartumcardiomyopathya pages 2-4)
Phenotype	Arrhythmia	HPO	HP:0011675	ECG abnormalities and arrhythmias, including atrial fibrillation and QTc prolongation, are common in PPCM.	(sigauke2024peripartumcardiomyopathya pages 5-7, sigauke2024peripartumcardiomyopathya pages 7-8)
Phenotype	Cardiogenic shock	HPO	HP:0031970	Severe PPCM may present with decompensated HF/cardiogenic shock and is a major cause of death.	(laskowska2026peripartumcardiomyopathycurrent pages 19-20, laskowska2026peripartumcardiomyopathy–whatisa pages 16-17)
Phenotype	Thromboembolism	HPO	HP:0001907	PPCM is associated with thromboembolic complications, especially in the hypercoagulable peripartum period.	(laskowska2026peripartumcardiomyopathycurrent pages 19-20, laskowska2026peripartumcardiomyopathy–whatisa pages 16-17, iannaccone2024diagnosisandmanagement pages 4-5)
Biological process	Response to oxidative stress	GO	GO:0006979	Oxidative stress is a central upstream mechanism linked to prolactin cleavage and endothelial/cardiomyocyte injury.	(laskowska2026peripartumcardiomyopathycurrent pages 4-5, sigauke2024peripartumcardiomyopathya pages 2-4, sigauke2024peripartumcardiomyopathya pages 4-5)
Biological process	Angiogenesis	GO	GO:0001525	Anti-angiogenic imbalance with elevated sFlt1 and reduced VEGF/PGC1α signaling is implicated in PPCM.	(laskowska2026peripartumcardiomyopathycurrent pages 4-5, sigauke2024peripartumcardiomyopathya pages 2-4, sigauke2024peripartumcardiomyopathya pages 4-5)
Biological process	Regulation of angiogenesis	GO	GO:0045765	Reviews emphasize dysregulated angiogenic signaling rather than simply angiogenesis itself.	(laskowska2026peripartumcardiomyopathycurrent pages 4-5, sigauke2024peripartumcardiomyopathya pages 4-5)
Biological process	Endothelial cell apoptotic process / endothelial dysfunction	GO		16-kDa prolactin/vasoinhibin and sFlt1 promote endothelial damage and vascular dysfunction in PPCM.	(laskowska2026peripartumcardiomyopathycurrent pages 4-5, sigauke2024peripartumcardiomyopathya pages 2-4, sigauke2024peripartumcardiomyopathya pages 4-5)
Biological process	Apoptotic process in cardiac muscle cells	GO	GO:0006915	Pathogenic prolactin fragment and vasculo-hormonal stress contribute to cardiomyocyte apoptosis.	(laskowska2026peripartumcardiomyopathycurrent pages 4-5, sigauke2024peripartumcardiomyopathya pages 4-5)
Biological process	Inflammatory response	GO	GO:0006954	Inflammation/autoimmunity is repeatedly cited as part of PPCM pathophysiology.	(sigauke2024peripartumcardiomyopathya pages 4-5)
Biological process	microRNA-mediated gene silencing / miRNA-mediated regulation	GO		miR-146a is a recurrent mechanistic marker linking endothelial stress to cardiomyocyte dysfunction.	(sigauke2024peripartumcardiomyopathya pages 2-4, sigauke2024peripartumcardiomyopathya pages 5-7)
Cell type	Cardiac muscle cell	CL	CL:0000746	Cardiac muscle cells are the main injured contractile cells underlying LV dysfunction.	(laskowska2026peripartumcardiomyopathycurrent pages 4-5, sigauke2024peripartumcardiomyopathya pages 4-5)
Cell type	Cardiomyocyte	CL		Reviews specifically refer to cardiomyocyte dysfunction/apoptosis as a downstream effect.	(laskowska2026peripartumcardiomyopathycurrent pages 4-5, sigauke2024peripartumcardiomyopathya pages 2-4, sigauke2024peripartumcardiomyopathya pages 4-5)
Cell type	Endothelial cell	CL	CL:0000115	Endothelial dysfunction is a key mechanistic node in the prolactin/sFlt1 model of PPCM.	(laskowska2026peripartumcardiomyopathycurrent pages 4-5, sigauke2024peripartumcardiomyopathya pages 2-4, sigauke2024peripartumcardiomyopathya pages 4-5)
Cell type	Trophoblast cell	CL	CL:0000351	Placental anti-angiogenic factor sFlt1 is implicated; trophoblast lineage is the likely placental source annotation.	(laskowska2026peripartumcardiomyopathycurrent pages 4-5, iannaccone2024diagnosisandmanagement pages 1-2, sigauke2024peripartumcardiomyopathya pages 2-4)
Anatomical structure	Left ventricle	UBERON	UBERON:0002084	LV structure/function is central to diagnosis, imaging, and outcome assessment in PPCM.	(iannaccone2024diagnosisandmanagement pages 1-2, sigauke2024peripartumcardiomyopathya pages 1-2, sigauke2024peripartumcardiomyopathya pages 7-8)
Anatomical structure	Myocardium	UBERON	UBERON:0002349	PPCM is a myocardial disease causing ventricular systolic dysfunction.	(yusuf2025advancingourunderstanding pages 1-2, sigauke2024peripartumcardiomyopathya pages 1-2)
Anatomical structure	Cardiac vasculature	UBERON		Vascular/endothelial injury and anti-angiogenic signaling are core mechanistic themes.	(laskowska2026peripartumcardiomyopathycurrent pages 4-5, sigauke2024peripartumcardiomyopathya pages 2-4, sigauke2024peripartumcardiomyopathya pages 4-5)
Anatomical structure	Placenta	UBERON	UBERON:0001987	Placenta is implicated as the source of circulating anti-angiogenic factors such as sFlt1.	(laskowska2026peripartumcardiomyopathycurrent pages 4-5, iannaccone2024diagnosisandmanagement pages 1-2, sigauke2024peripartumcardiomyopathya pages 2-4)
Intervention	Beta-blocker therapy	MAXO		Standard HF pharmacotherapy in PPCM includes beta-blockers when appropriate.	(yusuf2025advancingourunderstanding pages 1-2, iannaccone2024diagnosisandmanagement pages 4-5, sigauke2024peripartumcardiomyopathya media 4d9eef0c)
Intervention	ACE inhibitor therapy postpartum	MAXO		ACE inhibitors are part of postpartum HFrEF management; avoided during pregnancy but used after delivery.	(yusuf2025advancingourunderstanding pages 1-2, iannaccone2024diagnosisandmanagement pages 4-5, sigauke2024peripartumcardiomyopathya media 4d9eef0c)
Intervention	Diuretic therapy	MAXO		Diuretics are used for symptomatic congestion/acute HF in PPCM.	(yusuf2025advancingourunderstanding pages 1-2, sigauke2024peripartumcardiomyopathya media 4d9eef0c)
Intervention	Anticoagulation	MAXO		Guidelines recommend anticoagulation in severe LV dysfunction and when bromocriptine is used.	(iannaccone2024diagnosisandmanagement pages 4-5, NCT05180773 chunk 1, NCT02590601 chunk 1)
Intervention	Bromocriptine therapy	MAXO		Bromocriptine is the main disease-targeted therapy under study, based on prolactin inhibition.	(iannaccone2024diagnosisandmanagement pages 1-2, kumar2023prolactininhibitionin pages 4-6, kumar2023prolactininhibitionin pages 1-3, NCT05180773 chunk 1)
Intervention	Mechanical circulatory support	MAXO		Severe PPCM may require ECMO/LVAD/BiVAD as bridge to recovery or transplant.	(laskowska2026peripartumcardiomyopathycurrent pages 19-20, iannaccone2024diagnosisandmanagement pages 4-5)

Table: This table proposes ontology-linked annotations for peripartum cardiomyopathy across phenotypes, mechanisms, cell types, anatomy, and interventions. It is useful as a compact starting point for disease knowledge-base curation grounded in the extracted evidence.

Visual evidence: management algorithm

A treatment flowchart for PPCM pharmacologic management (pregnancy vs postpartum) was retrieved from the 2024 comprehensive review. (sigauke2024peripartumcardiomyopathya media 4d9eef0c)

Limitations of this evidence package (important for curation)

Many template elements (ICD/MeSH/MONDO/Orphanet IDs; ClinVar variant-level annotations; gnomAD frequencies; robust protective factors; detailed animal model descriptions) were not present in the retrieved evidence excerpts and cannot be safely inferred here.
Several key sources used are narrative reviews; while they summarize primary literature, they are not themselves primary trials/registries. Where possible, this report emphasizes quantitative findings and direct abstract quotes from 2023–2024 systematic reviews and cohort studies.

References

(sigauke2024peripartumcardiomyopathya pages 1-2): Farai Russell Sigauke, Hopewell Ntsinjana, and Nqoba Tsabedze. Peripartum cardiomyopathy: a comprehensive and contemporary review. Heart Failure Reviews, 29:1261-1278, Sep 2024. URL: https://doi.org/10.1007/s10741-024-10435-5, doi:10.1007/s10741-024-10435-5. This article has 36 citations and is from a peer-reviewed journal.
(sigauke2024peripartumcardiomyopathya pages 5-7): Farai Russell Sigauke, Hopewell Ntsinjana, and Nqoba Tsabedze. Peripartum cardiomyopathy: a comprehensive and contemporary review. Heart Failure Reviews, 29:1261-1278, Sep 2024. URL: https://doi.org/10.1007/s10741-024-10435-5, doi:10.1007/s10741-024-10435-5. This article has 36 citations and is from a peer-reviewed journal.
(iannaccone2024diagnosisandmanagement pages 1-2): Giulia Iannaccone, Francesca Graziani, Polona Kacar, Pietro Paolo Tamborrino, Rosa Lillo, Claudia Montanaro, Francesco Burzotta, and Michael A. Gatzoulis. Diagnosis and management of peripartum cardiomyopathy and recurrence risk. International Journal of Cardiology Congenital Heart Disease, 17:100530, Sep 2024. URL: https://doi.org/10.1016/j.ijcchd.2024.100530, doi:10.1016/j.ijcchd.2024.100530. This article has 11 citations.
(kumar2023prolactininhibitionin pages 4-6): Amudha Kumar, Ramya Ravi, Ranjith K. Sivakumar, Vignesh Chidambaram, Marie G. Majella, Shashank Sinha, Luigi Adamo, Emily S. Lau, Subhi J. Al'Aref, Aarti Asnani, Garima Sharma, and Jawahar L. Mehta. Prolactin inhibition in peripartum cardiomyopathy: systematic review and meta-analysis. Current Problems in Cardiology, 48:101461, Feb 2023. URL: https://doi.org/10.1016/j.cpcardiol.2022.101461, doi:10.1016/j.cpcardiol.2022.101461. This article has 38 citations and is from a peer-reviewed journal.
(sigauke2024peripartumcardiomyopathya pages 2-4): Farai Russell Sigauke, Hopewell Ntsinjana, and Nqoba Tsabedze. Peripartum cardiomyopathy: a comprehensive and contemporary review. Heart Failure Reviews, 29:1261-1278, Sep 2024. URL: https://doi.org/10.1007/s10741-024-10435-5, doi:10.1007/s10741-024-10435-5. This article has 36 citations and is from a peer-reviewed journal.
(noll2024breastfeedinginpatients pages 1-2): Angelina Noll, Kris R. Kawamoto, Maya T. Dassanayake, Laura Leuenberger, Stephanie M. Spehar, Jenny Wu, Elizabeth Langen, and Melinda B. Davis. Breastfeeding in patients with peripartum cardiomyopathy: clinical outcomes and physician counseling. International Breastfeeding Journal, Oct 2024. URL: https://doi.org/10.1186/s13006-024-00673-6, doi:10.1186/s13006-024-00673-6. This article has 7 citations and is from a peer-reviewed journal.
(sigauke2024peripartumcardiomyopathya pages 4-5): Farai Russell Sigauke, Hopewell Ntsinjana, and Nqoba Tsabedze. Peripartum cardiomyopathy: a comprehensive and contemporary review. Heart Failure Reviews, 29:1261-1278, Sep 2024. URL: https://doi.org/10.1007/s10741-024-10435-5, doi:10.1007/s10741-024-10435-5. This article has 36 citations and is from a peer-reviewed journal.
(laskowska2026peripartumcardiomyopathy–whatisa pages 3-5): M Laskowska. Peripartum cardiomyopathy–what is worth knowing when a young mother's heart is diseased? a review. Unknown journal, 2026.
(yusuf2025advancingourunderstanding pages 1-2): I Yusuf, A Enenche, and R Adefila. Advancing our understanding of peripartum cardiomyopathy: current evidence and future directions. Unknown journal, 2025.
(sigauke2024peripartumcardiomyopathya pages 7-8): Farai Russell Sigauke, Hopewell Ntsinjana, and Nqoba Tsabedze. Peripartum cardiomyopathy: a comprehensive and contemporary review. Heart Failure Reviews, 29:1261-1278, Sep 2024. URL: https://doi.org/10.1007/s10741-024-10435-5, doi:10.1007/s10741-024-10435-5. This article has 36 citations and is from a peer-reviewed journal.
(laskowska2026peripartumcardiomyopathycurrent pages 19-20): Marzena Laskowska. Peripartum cardiomyopathy: current insights into pathogenesis and clinical management: a narrative review. Journal of Clinical Medicine, 15:2974, Apr 2026. URL: https://doi.org/10.3390/jcm15082974, doi:10.3390/jcm15082974. This article has 0 citations.
(iannaccone2024diagnosisandmanagement pages 4-5): Giulia Iannaccone, Francesca Graziani, Polona Kacar, Pietro Paolo Tamborrino, Rosa Lillo, Claudia Montanaro, Francesco Burzotta, and Michael A. Gatzoulis. Diagnosis and management of peripartum cardiomyopathy and recurrence risk. International Journal of Cardiology Congenital Heart Disease, 17:100530, Sep 2024. URL: https://doi.org/10.1016/j.ijcchd.2024.100530, doi:10.1016/j.ijcchd.2024.100530. This article has 11 citations.
(NCT02590601 chunk 1): Marc Jolicoeur. Bromocriptine in the Treatment of Peripartum Cardiomyopathy. Montreal Heart Institute. 2017. ClinicalTrials.gov Identifier: NCT02590601
(wijayanto2024outcomesofsubsequent pages 1-1): Matthew Aldo Wijayanto, Risalina Myrtha, Graciella Angelica Lukas, Annisa Aghnia Rahma, Shafira Nur Hanifa, Hadiqa Almas Zahira, and Muhana Fawwazy Ilyas. Outcomes of subsequent pregnancy in women with peripartum cardiomyopathy: a systematic review and meta-analysis. Open Heart, 11:e002626, Apr 2024. URL: https://doi.org/10.1136/openhrt-2024-002626, doi:10.1136/openhrt-2024-002626. This article has 17 citations and is from a peer-reviewed journal.
(wijayanto2024outcomesofsubsequent pages 3-4): Matthew Aldo Wijayanto, Risalina Myrtha, Graciella Angelica Lukas, Annisa Aghnia Rahma, Shafira Nur Hanifa, Hadiqa Almas Zahira, and Muhana Fawwazy Ilyas. Outcomes of subsequent pregnancy in women with peripartum cardiomyopathy: a systematic review and meta-analysis. Open Heart, 11:e002626, Apr 2024. URL: https://doi.org/10.1136/openhrt-2024-002626, doi:10.1136/openhrt-2024-002626. This article has 17 citations and is from a peer-reviewed journal.
(laskowska2026peripartumcardiomyopathy–whatisa pages 16-17): M Laskowska. Peripartum cardiomyopathy–what is worth knowing when a young mother's heart is diseased? a review. Unknown journal, 2026.
(sigauke2024peripartumcardiomyopathya media 4d9eef0c): Farai Russell Sigauke, Hopewell Ntsinjana, and Nqoba Tsabedze. Peripartum cardiomyopathy: a comprehensive and contemporary review. Heart Failure Reviews, 29:1261-1278, Sep 2024. URL: https://doi.org/10.1007/s10741-024-10435-5, doi:10.1007/s10741-024-10435-5. This article has 36 citations and is from a peer-reviewed journal.
(iannaccone2024diagnosisandmanagement pages 5-6): Giulia Iannaccone, Francesca Graziani, Polona Kacar, Pietro Paolo Tamborrino, Rosa Lillo, Claudia Montanaro, Francesco Burzotta, and Michael A. Gatzoulis. Diagnosis and management of peripartum cardiomyopathy and recurrence risk. International Journal of Cardiology Congenital Heart Disease, 17:100530, Sep 2024. URL: https://doi.org/10.1016/j.ijcchd.2024.100530, doi:10.1016/j.ijcchd.2024.100530. This article has 11 citations.
(NCT05180773 chunk 1): Dennis M. McNamara, MD, MS. Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy. Dennis M. McNamara, MD, MS. 2022. ClinicalTrials.gov Identifier: NCT05180773
(NCT00998556 chunk 1): Denise Hilfiker-Kleiner, PhD. Effect of Bromocriptine on Left Ventricular Function in Women With Peripartum Cardiomyopathy. Hannover Medical School. 2010. ClinicalTrials.gov Identifier: NCT00998556
(laskowska2026peripartumcardiomyopathycurrent pages 4-5): Marzena Laskowska. Peripartum cardiomyopathy: current insights into pathogenesis and clinical management: a narrative review. Journal of Clinical Medicine, 15:2974, Apr 2026. URL: https://doi.org/10.3390/jcm15082974, doi:10.3390/jcm15082974. This article has 0 citations.
(kumar2023prolactininhibitionin pages 1-3): Amudha Kumar, Ramya Ravi, Ranjith K. Sivakumar, Vignesh Chidambaram, Marie G. Majella, Shashank Sinha, Luigi Adamo, Emily S. Lau, Subhi J. Al'Aref, Aarti Asnani, Garima Sharma, and Jawahar L. Mehta. Prolactin inhibition in peripartum cardiomyopathy: systematic review and meta-analysis. Current Problems in Cardiology, 48:101461, Feb 2023. URL: https://doi.org/10.1016/j.cpcardiol.2022.101461, doi:10.1016/j.cpcardiol.2022.101461. This article has 38 citations and is from a peer-reviewed journal.

Key Findings ▸

Key Findings

Angiogenic imbalance is the primary vascular mechanism: elevated sFlt1 from the placenta antagonizes VEGF/PlGF signaling, causing endothelial dysfunction and impaired cardiac angiogenesis (PMID:22596155)
16-kDa prolactin is a central mediator: STAT3 deficiency leads to enhanced cathepsin D activity, cleaving prolactin into a cardiotoxic 16-kDa fragment that is anti-angiogenic and pro-apoptotic (PMID:17289576)
Bromocriptine shows therapeutic promise: blocks prolactin secretion, preventing 16-kDa fragment generation; proof-of-concept RCT showed LVEF recovery from 27% to 58% vs 36% with standard therapy alone (PMID:20308616)
TTN truncating variants are the most common genetic risk factor, found in ~10% of PPCM patients, similar to the prevalence in dilated cardiomyopathy (PMID:26735901)
Preeclampsia is present in 22% of PPCM cases (4x background rate), sharing anti-angiogenic pathobiology (PMID:24013055)
Autoimmune mechanisms including anti-M2 muscarinic receptor autoantibodies independently predict worse cardiac recovery (PMID:34963460)
Prognosis: ~10% mortality; >50% recover LV function within 1 year; high relapse risk in subsequent pregnancies (PMID:37414337)

Ask OpenScientist

OpenScientist Report

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Environmental Factors

Clinical Trials

Source YAML

References & Deep Research

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Comprehensive Disease Characteristics Report: Peripartum Cardiomyopathy (PPCM)

Executive summary

1. Disease information

1.1 What is PPCM?

1.2 Key identifiers (ICD/MeSH/MONDO/Orphanet/OMIM)

1.3 Evidence source type

2. Etiology

2.1 Disease causal factors (multifactorial “two-hit” model)

2.2 Risk factors (with quantified estimates where available)

2.3 Protective factors

2.4 Gene–environment interaction

3. Phenotypes

3.1 Clinical phenotypes (symptoms/signs)

3.2 Phenotype characteristics and frequencies

3.3 Quality of life impact

3.4 Suggested HPO terms (examples)

4. Genetic / molecular information

4.1 Causal/susceptibility genes and estimated contribution

4.2 Variant types and functional consequences

4.3 Modifier genes / epigenetics / chromosomal abnormalities

5. Environmental information

6. Mechanism / pathophysiology

6.1 Core mechanistic framework (causal chain)

6.2 Suggested GO terms / CL terms / UBERON structures

7. Anatomical structures affected

7.1 Primary organ/system involvement

7.2 Pregnancy-associated structure

8. Temporal development

8.1 Onset

8.2 Progression and recovery

9. Inheritance and population

9.1 Epidemiology

9.2 Demographic disparities

9.3 Inheritance pattern

10. Diagnostics

10.1 Core diagnostic workflow (real-world)

10.2 Biomarkers (investigational)

10.3 Prognostic biomarker statistic

11. Outcome / prognosis

11.1 Maternal outcomes

11.2 Subsequent pregnancy outcomes (2024 meta-analysis)

11.3 Prognostic factors

12. Treatment

12.1 Guideline-directed HF therapy (application in practice)

12.2 Bromocriptine / prolactin inhibition (evidence and interpretation)

12.3 Anticoagulation

12.4 Mechanical support and transplant

12.5 Breastfeeding and real-world counseling